{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T21:15:45Z","timestamp":1784754945749,"version":"3.55.0"},"reference-count":67,"publisher":"Informa UK Limited","issue":"4","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Hematology"],"published-print":{"date-parts":[[2026,4,3]]},"DOI":"10.1080\/17474086.2026.2634283","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T02:26:49Z","timestamp":1771468009000},"page":"361-372","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Linvoseltamab, a BCMA-directed CD3 T-cell engager for multiple myeloma: a patient-centric option via a response-adapted dosing regimen"],"prefix":"10.1080","volume":"19","author":[{"given":"Jacob A.","family":"Lowy","sequence":"first","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael F.","family":"Rogers","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary M.","family":"Avigan","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus S.","family":"Flores","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Samuel","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad A.","family":"Rattu","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Richter","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27422"},{"key":"e_1_3_5_4_1","unstructured":"Cancer stat facts: myeloma. Epidemiology and end results program. Janssen Biotech Inc; 2025. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.134"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283191"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa01133202"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709974"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.92"},{"key":"e_1_3_5_10_1","unstructured":"Mayo Clinic. mSMART: multiple myeloma treatment guidelines. Mayo Clinic; 2025 [cited 2025 Oct 27]. Available from: https:\/\/www.msmart.org\/mm-treatment-guidelines"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01893"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31594-X"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00645-1"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.0003"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2400712"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2505133"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312054"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00263-0"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03485-7"},{"key":"e_1_3_5_20_1","unstructured":"Janssen Biotech Inc. New long-term progression-free survival data projections reinforce subcutaneous DARZALEX\u00ae (daratumumab) quadruplet therapy as a foundational standard of care for patients with newly diagnosed multiple myeloma. Janssen-Cilag International NV a Johnson & Johnson company. 2025. Johnson & Johnson Apr 23 [cited 2025 Nov 1]. Available from: https:\/\/www.jnj.com\/innovativemedicine\/emea\/newsroom\/new-long-term-progression-free-survival-data-projections-reinforce-subcutaneous-darzalex-daratumumab-quadruplet-therapy-as-a-foundational-standard-of-care-for-patients-with-newly-diagnosed-multiple-myeloma"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00966-9"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01139-y"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2514752"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.7505"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2025.2465825"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2025.101342"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02528-9"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204591"},{"key":"e_1_3_5_32_1","unstructured":"U.S. Food and Drug Administration. FDA requires boxed warning for T-Cell malignancies following treatment with BCMA-Directed or CD19-directed therapies. U.S. Food and Drug administration. 2023 Nov 8 [cited 2025 Oct 27]. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/safety-availability-biologics\/fda-requires-boxed-warning-t-cell-malignancies-following-treatment-bcma-directed-or-cd19-directed"},{"key":"e_1_3_5_33_1","unstructured":"U.S. Food and Drug Administration. FDA approves labeling changes to include boxed warning for immune effector cell\u2013associated enterocolitis. U.S. Food and Drug administration. 2024 Nov 8 [cited 2025 Nov 1]. Available from: https:\/\/www.fda.gov\/safety\/medical-product -safety-information\/fda-approves-labeling-changes-include-boxed-warning-immune-effector-cell-associated-enterocolitis"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.19462"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-011200"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024026212"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023012354"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells14141077"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-24-0118"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002736"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8034"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.7540"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-208192"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.136"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025016613"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.01008"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(25)03516-5"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(25)03538-4"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(25)03586-4"},{"key":"e_1_3_5_50_1","unstructured":"Regeneron Pharmaceuticals Inc. Linvoseltamab BLA for treatment of relapsed\/refractory multiple myeloma accepted for FDA priority review. Tarrytown (NY): Regeneron Pharmaceuticals Inc. Available from: https:\/\/investor.regeneron.com\/news-releases\/news-release-details\/linvoseltamab-bla-treatment-relapsedrefractory-multiple-myeloma"},{"key":"e_1_3_5_51_1","unstructured":"Regeneron Pharmaceuticals Inc. Regeneron provides update on biologics license application for linvoseltamab. Tarrytown (NY): Regeneron Pharmaceuticals Inc. Available from: https:\/\/investor.regeneron.com\/news-releases\/news-release-details\/regeneron-provides-update-biologics-license-application-0"},{"key":"e_1_3_5_52_1","unstructured":"Regeneron Pharmaceuticals Inc. Lynozyfic\u2122 (linvoseltamab) approved in the European Union for the treatment of relapsed\/refractory multiple myeloma. Tarrytown (NY): Regeneron Pharmaceuticals Inc. Available from: https:\/\/investor.regeneron.com\/news-releases\/news-release-details\/lynozyfictm-linvoseltamab-approved-european-union-treatment"},{"key":"e_1_3_5_53_1","unstructured":"Regeneron Pharmaceuticals Inc. Lynozyfic\u2122 (linvoseltamab-gcpt) receives FDA accelerated approval for treatment of relapsed or refractory multiple myeloma. Tarrytown (NY): Regeneron Pharmaceuticals Inc. Available from: https:\/\/investor.regeneron.com\/news-releases\/news-release-details\/lynozyfictm-linvoseltamab-gcpt-receives-fda-accelerated-approval"},{"key":"e_1_3_5_54_1","unstructured":"Regeneron Pharmaceuticals Inc. Linvoseltamab in combination with carfilzomib or bortezomib shows promising Initial results in earlier lines of treatment for relapsed\/refractory multiple myeloma. Tarrytown (NY): Regeneron Pharmaceuticals Inc. Available from: https:\/\/newsroom.regeneron.com\/news-releases\/news-release-details\/linvoseltamab-combination-carfilzomib-or-bortezomib-shows"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.7513"},{"key":"e_1_3_5_56_1","unstructured":"Regeneron Pharmaceuticals Inc. Linvoseltamab BLA for the treatment of relapsed\/refractory multiple myeloma. Regeneron investor relations news release. Regeneron; 2023 Dec 13 [cited 2025 Oct 27]. https:\/\/investor.regeneron.com\/news-releases\/news-release-details\/linvoseltamab-bla-treatment-relapsedrefractory-multiple-myeloma"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(25)04011-X"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(25)03494-9"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-697"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.7536"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-181228"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.2165\/11538370-000000000-00000"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(24)02304-8"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(24)02317-6"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(25)03517-7"},{"key":"e_1_3_5_66_1","unstructured":"Regeneron Pharmaceuticals Inc. Lynozyfic (Linvoseltamab-Gcpt) Regeneron 2025 [cited 2025 Oct 27]. Available from: https:\/\/www.lynozyfic.com\/"},{"key":"e_1_3_5_67_1","unstructured":"Janssen Biotech Inc. Tecvayli (teclistamab-cqyv) HCP website. Janssen Biotech; 2025 [cited 2025 Oct 27]. Available from: https:\/\/www.tecvaylihcp.com\/"},{"key":"e_1_3_5_68_1","unstructured":"Pfizer Inc. Elrexfio (elranatamab-bcmm) HCP Website. Pfizer; 2025 [cited 2025 Oct 27]. Available from: https:\/\/elrexfio.pfizerpro.com\/"},{"key":"e_1_3_5_69_1","unstructured":"Janssen Biotech Inc. Talvey (talquetamab-tgvs) HCP website. Janssen Biotech; 2025 [cited 2025 Oct 27]. Available from: https:\/\/www.talveyhcp.com\/"}],"updated-by":[{"DOI":"10.1080\/17474086.2026.2647574","type":"addendum","label":"Addendum","source":"publisher","updated":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000}},{"DOI":"10.1080\/17474086.2026.2647574","type":"addendum","label":"Addendum","source":"publisher","updated":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000}}],"container-title":["Expert Review of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17474086.2026.2634283","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T10:39:15Z","timestamp":1775039955000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17474086.2026.2634283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":67,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4,3]]}},"alternative-id":["10.1080\/17474086.2026.2634283"],"URL":"https:\/\/doi.org\/10.1080\/17474086.2026.2634283","relation":{},"ISSN":["1747-4086","1747-4094"],"issn-type":[{"value":"1747-4086","type":"print"},{"value":"1747-4094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-11-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}